The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis
Year: 2022
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: Background: The aim of this study was to systematically synthesise the global evidence on the prevalence of persistent symptoms in a general post COVID-19 population. Methods: A systematic literature search was conducted using multiple electronic databases (MEDLINE and The Cochrane Library, Scopus, CINAHL, and medRxiv) until January 2022. Studies with at least 100 people with confirmed or self-reported COVID-19 symptoms at ≥28 days following infection onset were included. Patient-reported outcome measures and clinical investigations were both assessed. Results were analysed descriptively, and meta-analyses were conducted to derive prevalence estimates. This study was pre-registered (PROSPERO-ID: CRD42021238247). Findings: 194 studies totalling 735,006 participants were included, with five studies conducted in those <18 years of age. Most studies were conducted in Europe (n = 106) or Asia (n = 49), and the time to follow-up ranged from ≥28 days to 387 days. 122 studies reported data on hospitalised patients, 18 on non-hospitalised, and 54 on hospitalised and non-hospitalised combined (mixed). On average, at least 45% of COVID-19 survivors, regardless of hospitalisation status, went on to experience at least one unresolved symptom (mean follow-up 126 days). Fatigue was frequently reported across hospitalised (28.4%; 95% CI 24.7%-32.5%), non-hospitalised (34.8%; 95% CI 17.6%-57.2%), and mixed (25.2%; 95% CI 17.7%-34.6%) cohorts. Amongst the hospitalised cohort, abnormal CT patterns/x-rays were frequently reported (45.3%; 95% CI 35.3%-55.7%), alongside ground glass opacification (41.1%; 95% CI 25.7%-58.5%), and impaired diffusion capacity for carbon monoxide (31.7%; 95% CI 25.8%-3.2%). Interpretation: Our work shows that 45% of COVID-19 survivors, regardless of hospitalisation status, were experiencing a range of unresolved symptoms at ∼ 4 months. Current understanding is limited by heterogeneous study design, follow-up durations, and measurement methods. Definition of subtypes of Long Covid is unclear, subsequently hampering effective treatment/management strategies. Funding: No funding.
Source: EClinicalMedicine
Authors: Lauren L. O'Mahoney, Ash Routen, Clare Gillies, Winifred Ekezie, Anneka Welford, Alexa Zhang, Urvi Karamchandani, Nikita Simms-Williams, Shabana Cassambai, Ashkon Ardavani, Thomas J. Wilkinson, Grace Hawthorne, Ffion Curtis, Andrew P. Kingsnorth, Abdullah Almaqhawi, Thomas Ward, Daniel Ayoubkhani, Amitava Banerjee, Melanie Calvert, Roz Shafran, Terence Stephenson, Jonathan Sterne, Helen Ward, Rachael A. Evans, Francesco Zaccardi, Shaney Wright, Kamlesh Khunti
Institutions: University of Leicester, University College London, Imperial College London, University of Birmingham, King Faisal University, Office for National Statistics, NIHR Birmingham Biomedical Research Centre, University of Bristol, University Hospitals of Leicester NHS Trust, NIHR Leicester Biomedical Research Centre
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: long COVID, persistent symptoms, prevalence, hospitalized patients, non-hospitalized patients, fatigue, ground-glass opacities, diffusing capacity for carbon monoxide, long-term health effects, COVID-19 survivors, patient-reported outcomes, cardiovascular symptoms, neurological symptoms, psychiatric symptoms, musculoskeletal symptoms
Open Access status: gold
Estimated APC paid: $4,500
Awards: Symptom-based pathways to earlier diagnosis: how to improve health for sufferers of chronic breathlessness with a cost-effective approach., NIHR Senior Investigator Award, G369436576, G3759260752, REACT Long COVID (REACT-LC), NIHR Senior Investigator Award, Characterisation, determinants, mechanisms and consequences of the long-term effects of COVID-19: providing the evidence base for health care services, Non-hospitalised Children & young people (CYP) with Long Covid (The CLoCk Study), STIMULATE-ICP (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways), NIHR Senior Investigator Award
OpenAlex ID: W4310508485
